> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes with obesity
- URL: https://www.coios.me/glp-1-receptor-agonists-versus-sglt-2-inhibitors-in-type-2/
- Published: 2026-11-15T11:39:00.000Z
- Updated: 2026-11-15T12:24:00.000Z
- Description: In Clalit's medical records, liraglutide and dulaglutide matched SGLT-2 inhibitors on weight loss but lowered HbA1c more.
- Author: Daniel Ryan
- Tags: Health today, Obesity, diabetes and GLP-1, Israel, #peer-reviewed, #refines, #item, #source-2026-11, #score-65

This study used Clalit's medical records to compare GLP-1 receptor agonists with SGLT-2 inhibitors in type 2 diabetes and obesity. Target trials were emulated for 4,296 liraglutide, 11,159 dulaglutide and 5,041 semaglutide initiators, with inverse-probability weighting. Five-year weight loss with liraglutide and dulaglutide, at 6.4-7.3 kg, was similar to SGLT-2 inhibitors. At 18 months, semaglutide gave 2.6 kg (95% CI 1.2-4.0) more weight loss than SGLT-2 inhibitors. At 18 months HbA1c fell 0.4%, 0.7% and 0.6% more with liraglutide, dulaglutide and semaglutide, an advantage maintained throughout follow-up. The data are observational, and semaglutide follow-up ran only three years against five for the others.

*Why it is interesting: Long-term head-to-head randomised trials of these drug classes are lacking. These analyses extend short-term trial evidence to five years for liraglutide and dulaglutide.*

Source

[Diabetes, Obesity and Metabolism, 9 November 2026](https://doi.org/10.1111/dom.71515?ref=coios.me)

Paper

Effectiveness of GLP-1 RAs and SGLT-2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial

Authors

Silverbeck J, Roitman E, Vodonos Zilberg A, Balicer R, Dagan N, Hernán MA

DOI

10.1111/dom.71515

Type

Peer-reviewed article

Design

Target trial emulation in Clalit electronic medical records; 4296 liraglutide, 11159 dulaglutide, 5041 semaglutide initiators vs SGLT-2i, inverse-probability weighting, follow-up to 5 years (3 for semaglutide)

Verdict

Refines prior evidence

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)